Synopsis
Synopsis
0
JDMF
0
VMF
0
Australia
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Aerius
2. Clarinex
3. Descarboethoxyloratadine
4. Descarboethoxyloratadine Acetate
5. Neoclarityn
6. Sch 34117
7. Sch-34117
1. 100643-71-8
2. Clarinex
3. Descarboethoxyloratadine
4. Desloratidine
5. Neoclarityn
6. Aerius
7. Azomyr
8. Sch-34117
9. Denosin
10. Allex
11. Opulis
12. Sch 34117
13. 8-chloro-11-piperidin-4-ylidene-6,11-dihydro-5h-benzo[5,6]cyclohepta[1,2-b]pyridine
14. Descarboethoxyoratidine
15. Desloratadine Actavis
16. Dasselta
17. Desloratadine Teva
18. Mfcd00871949
19. 8-chloro-11-(piperidin-4-ylidene)-6,11-dihydro-5h-benzo[5,6]cyclohepta[1,2-b]pyridine
20. Nsc-759824
21. Chembl1172
22. Loratadine Related Compound A
23. 8-chloro-6,11-dihydro-11-(4-piperidinylidene)-5h-benzo(5,6)cyclohepta(1,2-b)pyridine
24. Mls000559042
25. Chebi:291342
26. Fvf865388r
27. Nsc675447
28. 5h-benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-(4-piperidinylidene)-
29. 13-chloro-2-piperidin-4-ylidene-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaene
30. Ncgc00159325-02
31. Smr000149358
32. Desloratadine [usan]
33. Clarinex Reditabs
34. 8-chloro-6,11-dihydro-11-(4-piperidinylidene)-5h-benzo[5,6]cyclohepta[1,2-b]pyridine
35. Dsstox_cid_24196
36. Dsstox_rid_80112
37. Dsstox_gsid_44196
38. Desalex
39. 5h-benzo(5,6)cyclohepta(1,2-b)pyridine, 8-chloro-6,11-dihydro-11-(4-piperidinylidene)-
40. 8-chloro-11-piperidin-4-ylidene-5,6-dihydrobenzo[1,2]cyclohepta[2,4-b]pyridine
41. 8-chloro-6,11-dihydro-11-(4-piperdinylidene)- 5h-benzo[5,6]cyclohepta[1,2-b]pyridine
42. Clarinex (tn)
43. 13-chloro-2-(piperidin-4-ylidene)-4-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaene
44. 8-chloro-11-(piperidin-4-ylidene)-6,11-dihydro-5h-benzo[5,6]cyclohepta[1,2-b]pyridine (descarboethoxyloratadine; Desloratadine)
45. Cas-100643-71-8
46. Sr-01000668962
47. Unii-fvf865388r
48. Desloratadine [usan:inn:ban]
49. 4-(8-chloro-5,6-dihydro-11h-benzo[5,6]cyclohepta(1,2-b]pyridin-11-ylidene)-piperidine
50. 4-(8-chloro-5,6-dihydro-11h-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine
51. 4-{8-chloro-5,6-dihydro-11h-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene}-piperidine
52. 4-{8-chloro-5,6-dihydro-11h-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene}piperidine
53. Desloratadine-[d7]
54. Desloratadine- Bio-x
55. Mk-4117
56. Cpd000149358
57. Opera_id_1891
58. Desloratadine [mi]
59. Desloratadine [inn]
60. Desloratadine [jan]
61. Schembl4425
62. Desloratadine [vandf]
63. Mls000759406
64. Mls001201801
65. Mls001424247
66. Desloratadine [mart.]
67. Sch34117
68. Desloratadine Ratiopharm
69. Desloratadine [usp-rs]
70. Desloratadine [who-dd]
71. Desloratadine (jan/usp/inn)
72. Gtpl7157
73. Zinc1261
74. Desloratadine [ema Epar]
75. Dtxsid1044196
76. Loratadine Related Compound A Rs
77. Hms2052h05
78. Hms2090c06
79. Hms2093f19
80. Hms3394h05
81. Hms3652o15
82. Hms3715j15
83. Hms3885c18
84. Pharmakon1600-01505393
85. Desloratadine [orange Book]
86. Albb-027276
87. Bcp02340
88. Desloratadine For System Suitability
89. Hy-b0539
90. Desloratadine [ep Monograph]
91. Tox21_111574
92. Bbl010777
93. Bdbm50073179
94. Desloratadine [usp Monograph]
95. Nsc759824
96. S4012
97. Stk586537
98. Akos000280921
99. Tox21_111574_1
100. Ac-1279
101. Ccg-101162
102. Db00967
103. Ks-1048
104. Nc00412
105. Nsc 675447
106. Nsc 759824
107. Nsc-675447
108. Sb17503
109. Clarinex-d Component Desloratadine
110. Desloratadine 100 Microg/ml In Methanol
111. Desloratadine, Powder, >=98% (hplc)
112. Ncgc00159325-03
113. Ncgc00159325-04
114. Ncgc00159325-05
115. Bd164361
116. Loratadine Ep Impurity D (desloratadine)
117. Sbi-0206828.p001
118. Loratadine Impurity D [ep Impurity]
119. D3787
120. Desloratadine Component Of Clarinex-d
121. Ft-0602522
122. Ft-0666048
123. Sw197792-3
124. A19515
125. D03693
126. H11943
127. Loratadine Related Compound A [usp-rs]
128. Ab00456701-11
129. Ab00456701-13
130. Ab00456701_14
131. Ab00456701_15
132. 643d718
133. L001025
134. Q418060
135. Loratadine Related Compound A [usp Impurity]
136. Q-200936
137. Rupatadine Fumarate Impurity B [ep Impurity]
138. Sr-01000668962-4
139. Sr-01000668962-5
140. Sr-01000668962-8
141. Brd-k82357231-001-13-4
142. Desloratadine Teva (authorized: Rhinitis, Urticaria)
143. Desloratadine Actavis (authorized: Rhinitis, Urticaria)
144. Desloratadine, European Pharmacopoeia (ep) Reference Standard
145. Desloratadine Ratiopharm (authorized: Rhinitis, Urticaria)
146. Desloratadine, United States Pharmacopeia (usp) Reference Standard
147. 4-(8-chloro-5,6-dihydro-11 H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine
148. 4-(8-chloro-5,6-dihydro-11h-benzo-[5,6]cyclohepta(1,2-b]pyridin-11-ylidene)-piperidine
149. 4-(8-chloro-5,6-dihydro-11h-benzo[5,6]cyclohepta [1,2-b]pyridin-11-ylidene) Piperidine
150. 4-(8-chloro-5,6-dihydro-11h-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene) Piperidine
151. 8-chloro-11-(4-piperidinylidene)-6,11-dihydro-5h- Benzo[4,5]cyclohepta[2,1-b]pyridine
152. 8-chloro-11-(4-piperidyliden)-6,11-dihydro-5h-benzo[5,6]cyclohepta [1,2-b]pyridine
153. 8-chloro-11-(4-piperidyliden)-6,11-dihydro-5h-benzo[5,6]cyclohepta[1,2-b]pyridine
154. 8-chloro-11-(4-piperidylidene)-6,11-dihydro-5h-benzo[5.6]cyclohepta[1,2-b]pyridine
155. 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5h-benzo[5,6]cyclohepta[1,2-b]pyridine
156. Desloratadine For System Suitability, European Pharmacopoeia (ep) Reference Standard
157. Desloratidine, Pharmaceutical Secondary Standard; Certified Reference Material
158. Loratadine Related Compound A, United States Pharmacopeia (usp) Reference Standard
159. 13-chloro-2-(piperidin-4-ylidene)-4-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3,5,7,12,14-hexaene
160. 8-chloro-11-(4-piperidylidene)-6,11-dihydro-5h-benzo[5,6]cyclohepta[1,2-b]pyridine
161. 8-chloro-6,11-dihydro-11(4-piperidylidene)-5h-benzo(5,6)cyclohepta(1,2-b) Pyridine
162. 8-chloro-6,11-dihydro-11-(4-piperidinylidene)-5h-benzo(5,6)cyclohepta(1,2-bpyridine
163. 8-chloro-6,11-dihydro-11-(4-piperidinylidene)-5h-benzo(5,6)cyclohepta(1,2b)pyridine
Molecular Weight | 310.8 g/mol |
---|---|
Molecular Formula | C19H19ClN2 |
XLogP3 | 4.5 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 0 |
Exact Mass | 310.1236763 g/mol |
Monoisotopic Mass | 310.1236763 g/mol |
Topological Polar Surface Area | 24.9 Ų |
Heavy Atom Count | 22 |
Formal Charge | 0 |
Complexity | 425 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 4 | |
---|---|
Drug Name | Clarinex |
PubMed Health | Desloratadine (By mouth) |
Drug Classes | Respiratory Agent |
Drug Label | CLARINEX (desloratadine) Tablets are light blue, round, film-coated tablets containing 5 mg desloratadine, an antihistamine, to be administered orally. CLARINEX Tablets also contain the following excipients: dibasic calcium phosphate dihydrate USP, m... |
Active Ingredient | Desloratadine |
Dosage Form | Tablet, orally disintegrating; Tablet; Syrup; Solution |
Route | oral; Oral |
Strength | 2.5mg; 5mg; 0.5mg/ml |
Market Status | Prescription |
Company | Merck Sharp Dohme; Schering |
2 of 4 | |
---|---|
Drug Name | Desloratadine |
PubMed Health | Desloratadine (By mouth) |
Drug Classes | Respiratory Agent |
Drug Label | Desloratadine tablets are blue, round, film-coated tablets debossed with logo L5 on one side containing 5 mg desloratadine, an antihistamine, to be administered orally. Desloratadine tablets also contain the following excipients: carnauba wax,... |
Active Ingredient | Desloratadine |
Dosage Form | Tablet, orally disintegrating; Tablet |
Route | oral; Oral |
Strength | 2.5mg; 5mg |
Market Status | Tentative Approval; Prescription |
Company | Perrigo R And D; Mylan Pharms; Glenmark Generics; Belcher Pharms; Lupin Pharms; Sun Pharm Inds; Reddys; Zydus Pharms Usa; Dr Reddys Labs; Sandoz; Orchid Hlthcare |
3 of 4 | |
---|---|
Drug Name | Clarinex |
PubMed Health | Desloratadine (By mouth) |
Drug Classes | Respiratory Agent |
Drug Label | CLARINEX (desloratadine) Tablets are light blue, round, film-coated tablets containing 5 mg desloratadine, an antihistamine, to be administered orally. CLARINEX Tablets also contain the following excipients: dibasic calcium phosphate dihydrate USP, m... |
Active Ingredient | Desloratadine |
Dosage Form | Tablet, orally disintegrating; Tablet; Syrup; Solution |
Route | oral; Oral |
Strength | 2.5mg; 5mg; 0.5mg/ml |
Market Status | Prescription |
Company | Merck Sharp Dohme; Schering |
4 of 4 | |
---|---|
Drug Name | Desloratadine |
PubMed Health | Desloratadine (By mouth) |
Drug Classes | Respiratory Agent |
Drug Label | Desloratadine tablets are blue, round, film-coated tablets debossed with logo L5 on one side containing 5 mg desloratadine, an antihistamine, to be administered orally. Desloratadine tablets also contain the following excipients: carnauba wax,... |
Active Ingredient | Desloratadine |
Dosage Form | Tablet, orally disintegrating; Tablet |
Route | oral; Oral |
Strength | 2.5mg; 5mg |
Market Status | Tentative Approval; Prescription |
Company | Perrigo R And D; Mylan Pharms; Glenmark Generics; Belcher Pharms; Lupin Pharms; Sun Pharm Inds; Reddys; Zydus Pharms Usa; Dr Reddys Labs; Sandoz; Orchid Hlthcare |
For the relief of symptoms of seasonal allergic rhinitis, perennial (non-seasonal) allergic rhinitis. Desloratidine is also used for the sympomatic treatment of pruritus and urticaria (hives) associated with chronic idiopathic urticaria.
FDA Label
Azomyr is indicated for the relief of symptoms associated with:
- allergic rhinitis (see section 5. 1)
- urticaria (see section 5. 1)
Aerius is indicated for the relief of symptoms associated with:
- allergic rhinitis;
- urticaria.
Neoclarityn is indicated for the relief of symptoms associated with:
- allergic rhinitis
- urticaria
Treatment of allergic rhinitis and urticaria.
Desloratadine Teva is indicated for the relief of symptoms associated with:
- allergic rhinitis;
- urticaria.
Dasselta is indicated for the relief of symptoms associated with:
- allergic rhinitis;
- urticaria.
Desloratadine ratiopharm is indicated in adults for the relief of symptoms associated with:
- allergic rhinitis
- chronic idiopathic urticaria as initially diagnosed by a physician
Aerius is indicated for the relief of symptoms associated with:
- allergic rhinitis (see section 5. 1)
- urticaria (see section 5. 1)
Opulis is indicated for the relief of symptoms associated with:
- allergic rhinitis (see section 5. 1)
- urticaria (see section 5. 1)
Desloratadine is a long-acting second-generation H1-receptor antagonist which has a selective and peripheral H1-antagonist action. Histamine is a chemical that causes many of the signs that are part of allergic reactions, such as the swelling of tissues. Histamine is released from histamine-storing cells (mast cells) and attaches to other cells that have receptors for histamine. The attachment of the histamine to the receptors causes the cell to be "activated," releasing other chemicals which produce the effects that we associate with allergies. Desloratadine blocks one type of receptor for histamine (the H1 receptor) and thus prevents activation of cells by histamine. Unlike most other antihistamines, Desloratadine does not enter the brain from the blood and, therefore, does not cause drowsiness.
Cholinergic Antagonists
Drugs that bind to but do not activate CHOLINERGIC RECEPTORS, thereby blocking the actions of ACETYLCHOLINE or cholinergic agonists. (See all compounds classified as Cholinergic Antagonists.)
Histamine H1 Antagonists, Non-Sedating
A class of non-sedating drugs that bind to but do not activate histamine receptors (DRUG INVERSE AGONISM), thereby blocking the actions of histamine or histamine agonists. These antihistamines represent a heterogenous group of compounds with differing chemical structures, adverse effects, distribution, and metabolism. Compared to the early (first generation) antihistamines, these non-sedating antihistamines have greater receptor specificity, lower penetration of BLOOD-BRAIN BARRIER, and are less likely to cause drowsiness or psychomotor impairment. (See all compounds classified as Histamine H1 Antagonists, Non-Sedating.)
R06AX27
R06AX27
R06AX27
R06AX27
R06AX27
R06AX27
R06AX27
R06AX27
R06AX27
R06AX27
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
R - Respiratory system
R06 - Antihistamines for systemic use
R06A - Antihistamines for systemic use
R06AX - Other antihistamines for systemic use
R06AX27 - Desloratadine
Absorption
Desloratadine administered orally for ten days to healthy volunteers as a 5 mg tablet once daily resulted in a mean Tmax of approximately 3 hours, a mean steady-state Cmax of 4 ng/ml, and a mean steady-state AUC of 56.9 ng\*hr/ml. A similar profile was observed using 10 ml of an oral solution containing 5 mg of desloratadine. Food was found not to affect desloratadine absorption.
Route of Elimination
Approximately 87% of a 14C-desloratadine dose was equally recovered in urine and feces as metabolic products.
Desloratadine is metabolized to the active metabolite 3-hydroxydesloratadine, which is subsequently glucuronidated.
Desloratadine is a known human metabolite of Rupatadine and loratadine.
S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560
Desloratadine has a mean plasma elimination half-life of approximately 27 hours.
Like other H1-blockers, Desloratadine competes with free histamine for binding at H1-receptors in the GI tract, uterus, large blood vessels, and bronchial smooth muscle. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms (eg. nasal congestion, watery eyes) brought on by histamine.
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19456
Submission : 2006-05-24
Status : Active
Type : II
Certificate Number : CEP 2014-321 - Rev 02
Issue Date : 2024-01-25
Type : Chemical
Substance Number : 2570
Status : Valid
Date of Issue : 2022-06-17
Valid Till : 2025-07-07
Written Confirmation Number : WC-0067
Address of the Firm :
NDC Package Code : 55111-073
Start Marketing Date : 2006-05-24
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Octavius has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.
Tagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.
Date of Issue : 2024-12-09
Valid Till : 2027-02-26
Written Confirmation Number : WC-0494
Address of the Firm :
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19456
Submission : 2006-05-24
Status : Active
Type : II
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19403
Submission : 2006-05-02
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21133
Submission : 2007-12-11
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19182
Submission : 2006-05-18
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19441
Submission : 2006-05-17
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19428
Submission : 2006-05-12
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19083
Submission : 2005-12-27
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-01-16
Pay. Date : 2014-01-10
DMF Number : 17652
Submission : 2004-09-07
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19339
Submission : 2006-04-11
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19508
Submission : 2006-06-07
Status : Inactive
Type : II
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Date of Issue : 2022-06-17
Valid Till : 2025-07-07
Written Confirmation Number : WC-0067
Address of the Firm : Chemical Technical Operations Unit-VI, APIIC Industrial Estate, Pydibhimavaram V...
Tagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.
Date of Issue : 2024-12-09
Valid Till : 2027-02-26
Written Confirmation Number : WC-0494
Address of the Firm : Unit-1, Sy. No.29, Tupakulagudem (Village), Pochavaram Panchayat, Tallapudi (Man...
Date of Issue : 2022-11-18
Valid Till : 2025-02-18
Written Confirmation Number : WC-0325
Address of the Firm : Plot No. 1408/1409, G.I.D.C,, Near Buch Plastic Unit 1, Ankleshwar, Dist-Bharuch...
Date of Issue : 2022-12-02
Valid Till : 2025-07-02
Written Confirmation Number : WC-0172
Address of the Firm : A-1, 401, 402 & 403 GIDC Ankleshwar, Bharuch India
Date of Issue : 2022-06-16
Valid Till : 2025-06-16
Written Confirmation Number : WC-0031
Address of the Firm : Unit-Lingojigudem (V) Choutuppal (M) Nalgonda District Talangana State India
Desloratadine EP / BP / USP / IH
Date of Issue : 2022-12-16
Valid Till : 2025-12-15
Written Confirmation Number : WC-0544
Address of the Firm : Plot No. 825,826,827, Industrial Area, Sector-Ill, Pithampur,\\r\\nDhar-454774, ...
Date of Issue : 2022-06-07
Valid Till : 2025-06-25
Written Confirmation Number : WC-0057n
Address of the Firm : Plot No. 3109, GIDC, Industrial Estate, Ankleshwar-393 002, Bharuch, Gujarat
Date of Issue : 2022-09-30
Valid Till : 2025-09-10
Written Confirmation Number : WC-0201
Address of the Firm : T-142, MIDC, Tarapur, Vil: Boisar, Dist: Thane-401 506, Maharashtra State
Date of Issue : 2022-06-03
Valid Till : 2025-07-02
Written Confirmation Number : WC-0060
Address of the Firm : Village- Masulkhana, Parwanoo, Distt.-Solan (Himachal Pradesh)
Date of Issue : 2022-06-08
Valid Till : 2025-07-25
Written Confirmation Number : WC-0159
Address of the Firm : A-7/A-8, MIDC, Ahmednagar-414 111, Maharashtra State
Registrant Name : Korea MSD Co., Ltd.
Registration Date : 2012-12-28
Registration Number : 20121228-179-I-98-03
Manufacturer Name : Schering-Plough (Avondale) C...
Manufacturer Address : Rathdrum, County Wicklow
Registrant Name : Korea Organon Co., Ltd.
Registration Date : 2020-04-02
Registration Number : 20200402-179-I-602-04
Manufacturer Name : MSD International GmbH(Singa...
Manufacturer Address : 50 Tuas West Drive Singapore 638408@Polígono Malpica Calle J No. 3-450016 Zaragoza S...
Registrant Name : Pami Future Co., Ltd.
Registration Date : 2012-08-31
Registration Number : 20120831-179-I-100-02
Manufacturer Name : Mylan Laboratories Limited
Manufacturer Address : Plot No. 14, 99 & 100, IDA Pashamylaram Phase-II, Patancheru, Sangareddy District - 5...
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
NDC Package Code : 55111-073
Start Marketing Date : 2006-05-24
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 65691-0057
Start Marketing Date : 2007-12-11
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 53104-7688
Start Marketing Date : 2016-01-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 53104-7613
Start Marketing Date : 2016-01-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 62331-019
Start Marketing Date : 2004-11-11
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 66039-830
Start Marketing Date : 2006-05-12
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 75895-0099
Start Marketing Date : 2001-12-21
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 62993-0805
Start Marketing Date : 2004-08-11
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 84206-0027
Start Marketing Date : 2024-08-08
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 66577-018
Start Marketing Date : 2006-09-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...
About the Company : DKSH, founded with the goal of improving people's lives, assists businesses with market expansion and business growth in both existing and emerging markets. It has been fostering g...
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
About the Company : Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfoli...
About the Company : Jai Radhe Sales was founded in 1999 as an out-of-the-box distribution firm specializing in the global supply of high-quality pharmaceutical ingredients. The firm provides complete ...
About the Company : Aptra Synthesis Private Limited, is a reliable and vertically integrated manufacturer of APIs and intermediates, boasting state-of-the-art manufacturing facilities that adhere to G...
About the Company : HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It...
Octavius has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.
About the Company : Octavius Pharma is a global leader in Directly Compressible Granules with over 40 years of experience in Formulation development, manufacturing and commercialization. It offers a w...
About the Company : Established in May 2012, Shandong Loncom Pharmaceutical operates as a fully owned subsidiary of Shandong Bestcomm Pharmaceutical Co., Ltd. Situated in the Qihe Economic Development...
Tagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.
About the Company : Tagoor Laboratories, established in 2018, is a part of the Tagoor Group. It specializes in providing APIs, advanced intermediates and key starting materials for critical and high-g...
About the Company : Atman Pharmaceuticals is a fully integrated pharmaceutical company that has distinguished itself as a leader in Bulk Drugs (API) marketing both domestically in India and overseas. ...
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
OCREVUS (ocrelizumab) is a humanised monoclonal antibody designed to target CD20-positive B cells, approved as a subcutaneous injection, for the treatment of multiple sclerosis.
Lead Product(s): Ocrelizumab,Dexamethasone,Desloratadine
Therapeutic Area: Neurology Brand Name: Ocrevus
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 25, 2024
Lead Product(s) : Ocrelizumab,Dexamethasone,Desloratadine
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Roche’s OCREVUS Subcutaneous Admin Approved as Twice-a-Year Injection for MS
Details : OCREVUS (ocrelizumab) is a humanised monoclonal antibody designed to target CD20-positive B cells, approved as a subcutaneous injection, for the treatment of multiple sclerosis.
Brand Name : Ocrevus
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 25, 2024
Details:
Ocrevus (ocrelizumab) is a twice-yearly subcutaneous injection designed to target CD20-positive B cells for treating progressive and relapsing multiple sclerosis.
Lead Product(s): Ocrelizumab,Dexamethasone,Desloratadine
Therapeutic Area: Neurology Brand Name: Ocrevus
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2024
Lead Product(s) : Ocrelizumab,Dexamethasone,Desloratadine
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Roche’s Subcutaneous OCREVUS Shows Strong One-Year Results in MS Patients
Details : Ocrevus (ocrelizumab) is a twice-yearly subcutaneous injection designed to target CD20-positive B cells for treating progressive and relapsing multiple sclerosis.
Brand Name : Ocrevus
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 17, 2024
Details:
OCREVUS (ocrelizumab) is a humanised monoclonal antibody designed to target CD20-positive B cells, which is being investigated as a a 10-minute subcutaneous injection, for the treatment of multiple sclerosis.
Lead Product(s): Ocrelizumab,Dexamethasone,Desloratadine
Therapeutic Area: Neurology Brand Name: Ocrevus
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2023
Lead Product(s) : Ocrelizumab,Dexamethasone,Desloratadine
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : OCREVUS (ocrelizumab) is a humanised monoclonal antibody designed to target CD20-positive B cells, which is being investigated as a a 10-minute subcutaneous injection, for the treatment of multiple sclerosis.
Brand Name : Ocrevus
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 13, 2023
CAS Number : 5570-77-4
End Use API : Desloratadine
About The Company : Vamsi Labs, established in 1991, is a leading Indian API manufacturer. Specializing in anti-asthmatic, anti-migraine & anti-psychotic APIs, it caters to domesti...
2-Cyano-3-[2(3-chloro phenyl) ethyl]pyridine (L-5)
CAS Number : 31255-57-9
End Use API : Desloratadine
About The Company : Tagoor Laboratories, established in 2018, is a part of the Tagoor Group. It specializes in providing APIs, advanced intermediates and key starting materials for...
CAS Number : 5570-77-4
End Use API : Desloratadine
About The Company : Tagoor Laboratories, established in 2018, is a part of the Tagoor Group. It specializes in providing APIs, advanced intermediates and key starting materials for...
8-Chloro-6,11-dihydro-11-(1-methyl-4-piperidinylid...
CAS Number : 38092-89-6
End Use API : Desloratadine
About The Company : Tagoor Laboratories, established in 2018, is a part of the Tagoor Group. It specializes in providing APIs, advanced intermediates and key starting materials for...
3(2-(3-Chloro phenyl) ethyl) cyano pyridine
CAS Number : 31255-55-7
End Use API : Desloratadine
About The Company : VASUDHA PHARMA CHEM LIMITED was incorporated, as a public limited company under the Companies Act, 1956 in 1994-95 at Hyderabad in the state of Telangana, India...
8-Chloro-5,6dihydro (1H)-benzo [5,6] cyclohepta (...
CAS Number : 31251-41-9
End Use API : Desloratadine
About The Company : VASUDHA PHARMA CHEM LIMITED was incorporated, as a public limited company under the Companies Act, 1956 in 1994-95 at Hyderabad in the state of Telangana, India...
8 chloro-11-[(N-Methyl)-4-piperidylidene]- 6, 11-d...
CAS Number : 38092-89-6
End Use API : Desloratadine
About The Company : VASUDHA PHARMA CHEM LIMITED was incorporated, as a public limited company under the Companies Act, 1956 in 1994-95 at Hyderabad in the state of Telangana, India...
cyclohepta (1,2b) pyridine (Methyl Loratadine)
CAS Number : 38092-89-6
End Use API : Desloratadine
About The Company : VASUDHA PHARMA CHEM LIMITED was incorporated, as a public limited company under the Companies Act, 1956 in 1994-95 at Hyderabad in the state of Telangana, India...
{3-[2-(3-chlorophenyl) ethyl] pyridine-2-yl} (1-me...
CAS Number : 119770-60-4
End Use API : Desloratadine
About The Company : VASUDHA PHARMA CHEM LIMITED was incorporated, as a public limited company under the Companies Act, 1956 in 1994-95 at Hyderabad in the state of Telangana, India...
CAS Number : 119770-60-4
End Use API : Desloratadine
About The Company : VASUDHA PHARMA CHEM LIMITED was incorporated, as a public limited company under the Companies Act, 1956 in 1994-95 at Hyderabad in the state of Telangana, India...
Regulatory Info : Registered in EU
Registration Country : Germany
Brand Name :
Dosage Form : Film Coated Tablet
Dosage Strength : 5MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Registered in EU
Registration Country : Germany
Packaging :
Regulatory Info : Registered in EU
Dosage : Film Coated Tablet
Dosage Strength : 5MG
Brand Name :
Approval Date :
Application Number :
Registration Country : Germany
Octavius has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Tablet
Dosage Strength : 5MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Octavius has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.
Packaging :
Regulatory Info :
Dosage : Tablet
Dosage Strength : 5MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Octavius has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.
Regulatory Info : DMF Available|FDF Compliance-U...
Registration Country : India
Brand Name :
Dosage Form : DC Granules
Dosage Strength : 5MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : DMF Available|FDF Compliance-U...
Registration Country : India
Octavius has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.
Packaging :
Regulatory Info : DMF Available|FDF Compliance-U...
Dosage : DC Granules
Dosage Strength : 5MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : Vietnam
Brand Name : SOSAllergy Syrup
Dosage Form : Syrup
Dosage Strength : 0.5MG/1ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Vietnam
Packaging :
Regulatory Info :
Dosage : Syrup
Dosage Strength : 0.5MG/1ML
Brand Name : SOSAllergy Syrup
Approval Date :
Application Number :
Registration Country : Vietnam
Regulatory Info :
Registration Country : Turkey
Brand Name : DEOXYKOL
Dosage Form : Capsules
Dosage Strength : 2.5MG/5ML
Packaging : 150 ml Glass Bottle
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Turkey
Packaging : 150 ml Glass Bottle
Regulatory Info :
Dosage : Capsules
Dosage Strength : 2.5MG/5ML
Brand Name : DEOXYKOL
Approval Date :
Application Number :
Registration Country : Turkey
Regulatory Info : Generic
Registration Country : Bahrain
Brand Name : Dorasip
Dosage Form : SYRUP
Dosage Strength : 0.5MG/5ML
Packaging :
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : Bahrain
Packaging :
Regulatory Info : Generic
Dosage : SYRUP
Dosage Strength : 0.5MG/5ML
Brand Name : Dorasip
Approval Date :
Application Number :
Registration Country : Bahrain
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Tablet
Dosage Strength : 5MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging :
Regulatory Info :
Dosage : Tablet
Dosage Strength : 5MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : China
Brand Name :
Dosage Form : Dispersible Tablet
Dosage Strength : 5MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : China
Packaging :
Regulatory Info :
Dosage : Dispersible Tablet
Dosage Strength : 5MG
Brand Name :
Approval Date :
Application Number :
Registration Country : China
Regulatory Info :
Registration Country : Tunisia
Brand Name : Clarius
Dosage Form : Tablet
Dosage Strength : 5MG
Packaging : 15 /pack
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Tunisia
Packaging : 15 /pack
Regulatory Info :
Dosage : Tablet
Dosage Strength : 5MG
Brand Name : Clarius
Approval Date :
Application Number :
Registration Country : Tunisia
Regulatory Info :
Registration Country : U.A.E
Brand Name : Actilor
Dosage Form : Tablet
Dosage Strength : 5MG
Packaging : 3 x 10's
Approval Date :
Application Number :
Regulatory Info :
Registration Country : U.A.E
Packaging : 3 x 10's
Regulatory Info :
Dosage : Tablet
Dosage Strength : 5MG
Brand Name : Actilor
Approval Date :
Application Number :
Registration Country : U.A.E
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Dosage Form : Injectable / Parenteral
Grade : Parenteral
Brand Name : Lactose Monohydrate
Application : Parenteral
Excipient Details : Lactose monohydrate is used as a diluent in inhalation and lyophilized preparations.
Dosage Form : Injectable / Parenteral
Grade : Parenteral, Oral, Topical
Dosage Form : Injectable / Parenteral
Grade : Parenteral, Oral, Topical
Dosage Form : Softgels
Grade : Oral
Dosage Form : Tablet
Grade : Not Available
Application : Controlled & Modified Release
Excipient Details : Solubilization, dispersion, crystallization inhibition, instant release matrices & spray drying
Dosage Form : Tablet
Grade : Not Available
Application : Solubilizers
Excipient Details : Solubilization, dispersion, crystallization inhibition, instant release matrices & spray drying
Pharmacopoeia Ref : Ph. Eur., USP, JP: Povidone
Technical Specs : Not Available
Ingredient(s) : Povidone
Dosage Form : Capsule
Grade : Not Available
Application : Fillers, Diluents & Binders
Excipient Details : Tablet binding, thickener, stabilizers of suspensions, reduces sedimentation, crystallization inhibition.
Pharmacopoeia Ref : Ph. Eur., USP, JP: Povidone
Technical Specs : Not Available
Ingredient(s) : Povidone
Dosage Form : Tablet
Grade : Not Available
Application : Granulation
Excipient Details : For non-erodible matrices using direct compression, Controlled release matrix. Matrix former in transdermal patches and topical films.
Pharmacopoeia Ref : Ph. Eur., USP-NF, JP-JPE: 80 %...
Technical Specs : Not Available
Ingredient(s) : Povidone
Dosage Form : Tablet
Grade : Not Available
Application : Granulation
Excipient Details : Wetting agent, reduces disintegration time, Ionic solubilizer, high HLB anionic emulsifier for semi-solids and foams.
Pharmacopoeia Ref : Ph. Eur.: Sodium Laurilsulfate...
Technical Specs : Not Available
Ingredient(s) : Sodium Lauryl Sulfate
Dosage Form : Tablet
Grade : Not Available
Application : Film Formers & Plasticizers
Excipient Details : Liquid plasticizer with high ADI, hydrophilic solvent & humectant in emulsions, skin penetration enhancer in topical formulaitons.
Pharmacopoeia Ref : Ph. Eur., JP, FCC, USP
Technical Specs : Not Available
Ingredient(s) : Propylene Glycol
Dosage Form : Softgel Capsule
Grade : Not Available
Application : Thickeners and Stabilizers
Excipient Details : Structure-building consistency factor with dry feel, forms crystalline barrier on skin
Pharmacopoeia Ref : Ph. Eur., USP-NF, JP: Stearic ...
Technical Specs : Not Available
Ingredient(s) : Stearic Acid
Dosage Form : Orodispersible Tablet
Grade : Not Available
Application : Chewable & Orodispersible Aids
Excipient Details : Ludiflash is a ready-to-use orally disintegrating tablet (ODT) solution with superior mouthfeel.
Pharmacopoeia Ref : Ph. Eur., USP, JP: 90 % mannit...
Technical Specs : Not Available
Ingredient(s) : Crospovidone
Dosage Form : Tablet
Grade : Not Available
Application : Direct Compression
Excipient Details : Ready-to-use direct compression solution for tablets.
Dosage Form : Tablet
Grade : Not Available
Application : Direct Compression
Excipient Details : Ready-to-use direct compression solution for lozenges, chewables and effervescent tablets.
Pharmacopoeia Ref : Ph. Eur., USP/NF and J.P
Technical Specs : Not Available
Ingredient(s) : Povidone
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
A Desloratadine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Desloratadine, including repackagers and relabelers. The FDA regulates Desloratadine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Desloratadine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Desloratadine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Desloratadine supplier is an individual or a company that provides Desloratadine active pharmaceutical ingredient (API) or Desloratadine finished formulations upon request. The Desloratadine suppliers may include Desloratadine API manufacturers, exporters, distributors and traders.
click here to find a list of Desloratadine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Desloratadine DMF (Drug Master File) is a document detailing the whole manufacturing process of Desloratadine active pharmaceutical ingredient (API) in detail. Different forms of Desloratadine DMFs exist exist since differing nations have different regulations, such as Desloratadine USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Desloratadine DMF submitted to regulatory agencies in the US is known as a USDMF. Desloratadine USDMF includes data on Desloratadine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Desloratadine USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Desloratadine suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Desloratadine Drug Master File in Korea (Desloratadine KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Desloratadine. The MFDS reviews the Desloratadine KDMF as part of the drug registration process and uses the information provided in the Desloratadine KDMF to evaluate the safety and efficacy of the drug.
After submitting a Desloratadine KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Desloratadine API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Desloratadine suppliers with KDMF on PharmaCompass.
A Desloratadine CEP of the European Pharmacopoeia monograph is often referred to as a Desloratadine Certificate of Suitability (COS). The purpose of a Desloratadine CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Desloratadine EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Desloratadine to their clients by showing that a Desloratadine CEP has been issued for it. The manufacturer submits a Desloratadine CEP (COS) as part of the market authorization procedure, and it takes on the role of a Desloratadine CEP holder for the record. Additionally, the data presented in the Desloratadine CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Desloratadine DMF.
A Desloratadine CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Desloratadine CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Desloratadine suppliers with CEP (COS) on PharmaCompass.
A Desloratadine written confirmation (Desloratadine WC) is an official document issued by a regulatory agency to a Desloratadine manufacturer, verifying that the manufacturing facility of a Desloratadine active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Desloratadine APIs or Desloratadine finished pharmaceutical products to another nation, regulatory agencies frequently require a Desloratadine WC (written confirmation) as part of the regulatory process.
click here to find a list of Desloratadine suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Desloratadine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Desloratadine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Desloratadine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Desloratadine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Desloratadine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Desloratadine suppliers with NDC on PharmaCompass.
Desloratadine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Desloratadine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Desloratadine GMP manufacturer or Desloratadine GMP API supplier for your needs.
A Desloratadine CoA (Certificate of Analysis) is a formal document that attests to Desloratadine's compliance with Desloratadine specifications and serves as a tool for batch-level quality control.
Desloratadine CoA mostly includes findings from lab analyses of a specific batch. For each Desloratadine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Desloratadine may be tested according to a variety of international standards, such as European Pharmacopoeia (Desloratadine EP), Desloratadine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Desloratadine USP).
LOOKING FOR A SUPPLIER?